Blue Flower

Dear Madam, Dear Sir,

On behalf of the entire NOXXON team, I am pleased to welcome you to the Investor section of our website. NOXXON is a European biopharmaceutical company developing anti-cancer treatments targeting the tumor microenvironment and is listed on Euronext Growth in Paris.

Our mission is to significantly advance therapies and increase survival for cancer patients, including immuno-oncology approaches, such as checkpoint inhibitors, and standard therapies such as chemo- and radiotherapy.

In 2019, we continued to follow the patients in combination trial of NOX-A12 + immunotherapy in colorectal and pancreatic cancers which was conducted in collaboration with Merck & Co/MSD.   The study confirmed that NOX-A12 is safe and well-tolerated in advanced cancer patients both as a monotherapy and in combination with Keytruda®. Moreover, the encouraging survival data suggest that the combination of NOX-A12 with immunotherapy can impact the biology of the tumor in a clinically relevant manner. We intend to pursue large-scale trials in these indications with a right partner.

We initiated an additional combination trial of NOX-A12 with radiotherapy in first-line brain cancer patients, for whom there is little to no benefit from the current standard of care, in September 2019. Following the recruitment and treatment of the first patient, the Data Safety Monitoring Board confirmed the safety of the NOX-A12 radiotherapy combination and validated the recruitment of next patients within the trial. We therefore remain focused on reaching our goal of obtaining data from the first cohort of patients in mid-2020.

We are determined to continue working on enhancing a therapeutic impact of anti-cancer therapies by combining them with our compounds NOX-A12 and NOX-E36, and we look forward to keeping you updated as our efforts and activities progress.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer
NOXXON
 

• Download the initiation report on NOXXON by Arrowhead
➥ See all reports on NOXXON here

 

Aram Mangasarian, CEO de Noxxon, LeZoom19H BiotechFinances le 19 05 2020: Nous abordons dans cette conférence les questions d'actualité, leur impact sur l'entreprise et la vision d'Aram sur l'avenir de Noxxon, les relations avec les industriels et les investisseurs.
Aram Mangasarian Pdg Noxxon : "J'espère avoir des nouvelles intéressantes pour les investisseurs cette année". La Web TV à la rencontre des dirigeants au Biomed Event 2020
L’entretien avec Aram Mangasarian, PDG de Noxxon, dans Le journal des biotechs de Boursorama pour brosser les perspectives de la société et de ses deux produits NOX-A12 et NOX-E36.
Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017